SFJ Pharmaceuticals® announced its partner Apellis Pharmaceuticals has formed a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases including paroxysmal nocturnal hemoglobinuria (PNH).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Under the terms of the agreement, Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for pegcetacoplan, including for hematologic indications. The strategic partnership allows Apellis to leverage Sobi's commercial capabilities and leadership in hematology and rare diseases to drive potential first regulatory approval in PNH and accelerate its internationalization.